STOCK TITAN
  1. Home
  2. News
  3. BEAT

Heartbeam Inc - BEAT STOCK NEWS

Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.

HeartBeam, Inc. (Symbol: BEAT) is a cutting-edge medical technology company that focuses on developing and commercializing high-resolution ambulatory Electrocardiogram (ECG) solutions. These solutions are designed to detect and monitor cardiac diseases outside traditional healthcare settings, providing critical diagnostic capabilities in a more accessible manner.

HeartBeam's flagship product is an innovative, credit card-sized ECG device that is diagnostically equivalent to a cardiologist reading a patient's 12-lead ECG and examining the patient. This compact device integrates seamlessly with a cloud-based diagnostic expert system, offering a comprehensive and user-friendly solution for cardiac monitoring.

Notably, studies designed by Harvard Medical School faculty have demonstrated that HeartBeam's technology performs on par with, or better than, world-class cardiologists in diagnosing heart attacks. The system features personalized diagnostic thresholds and unique ECG markers that help pinpoint the location of a heart attack on a 3D heart model, enhancing the accuracy and depth of diagnostic information provided to healthcare professionals.

One of the key components of HeartBeam's technology is the iCardiologist application, which uses artificial intelligence and machine learning to continually improve its diagnostic accuracy and predictive capabilities. This application aids cardiologists by providing detailed patient analysis, thereby supporting more informed and timely medical decisions.

HeartBeam has developed a proprietary and patented Vector Electrocardiography (VECG) technology platform, which is the cornerstone of its high-resolution ECG solutions. The company has validated this platform and is in the process of seeking U.S. Food and Drug Administration (FDA) clearance for its initial telehealth products.

With its innovative approach and proven technology, HeartBeam is poised to make significant strides in the field of cardiac care, offering practical solutions that can be utilized outside traditional healthcare environments, thereby broadening access to critical diagnostic tools and improving patient outcomes.

Latest News: Source: HeartBeam, Inc.

  • ------
  • ------
  • ------
News

HeartBeam to Host Third Quarter 2023 Results Conference Call on Tuesday November 14, 2023 at 4:30 p.m. Eastern Time

Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) will hold a conference call on November 14, 2023, to discuss its Q3 2023 results and review recent announcements, ongoing initiatives, and anticipated 2024 milestones. The call will be hosted by CEO Branislav Vajdic, President Robert Eno, and CFO Richard Brounstein. A press release detailing the results will be issued prior to the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.73%
Tags
conferences earnings
-
News

Implicity Expands Senior Leadership Team with New U.S. Chief Commercial Officer

Rhea-AI Summary
Jon Hunt, a veteran in the medical device industry, has joined Implicity as its new Chief Commercial Officer (CCO), North America, to focus on business and sales strategies for the U.S. market. Implicity recently submitted for U.S. FDA clearance for a machine learning algorithm that can predict acute heart failure. The U.S. market for remote patient monitoring is expected to reach a value of more than $25 billion by 2028.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
management
-
News

HeartBeam Appoints Richa Gujarati and Pooja Chatterjee to Senior Management Team

Rhea-AI Summary
HeartBeam, Inc. appoints Richa Gujarati as Senior VP, Product, and Pooja Chatterjee as VP, Clinical. Gujarati will handle product roadmap and go-to-market strategy, while Chatterjee will lead the clinical pipeline for FDA clearances. Their expertise will support the commercialization of HeartBeam's ambulatory VECG products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
management
News

HeartBeam Reports Second Quarter 2023 Financial Results

Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) strengthens its Board of Directors and IP position, publishes a peer-reviewed article, and reports Q2 2023 operational and financial results. The company closed $26.5 million in financings, announced key additions to the board, and appointed a new Vice President of Regulatory Affairs. They also submitted a 510(k) application to the FDA for their HeartBeam AIMIGo™ System. Q2 2023 financial results show a net loss of $3.2 million and cash, cash equivalents, and short-term investments totaling approximately $21.3 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
earnings
-
News

HeartBeam Announces Publication of Foundational Study on the Detection of Heart Attacks

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.05%
Tags
none
-
News

HeartBeam Appoints Deborah Castillo as Vice President of Regulatory Affairs

Rhea-AI Summary
HeartBeam, Inc. has appointed Deborah Castillo, PhD, as Vice President of Regulatory Affairs. Castillo brings extensive experience in regulatory affairs and quality assurance for medical devices and diagnostics, with a focus on cardiovascular diseases and neuroscience. She will lead HeartBeam's regulatory affairs function and support the company's clinical development and commercialization efforts for its novel HeartBeam AIMIGo™ Platform Technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News

HeartBeam to Host Second Quarter 2023 Results Conference Call on Thursday August 10, 2023 at 4:30 p.m. Eastern Time

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News

HeartBeam Appoints Dr. Michael R. Jaff to the Board of Directors

Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) announces the appointment of Michael R. Jaff, DO, a renowned Vascular Physician and Researcher, to its board of directors. Dr. Jaff brings extensive clinical and industry experience, having held key positions at Boston Scientific Corporation and Harvard Medical School. This move strengthens HeartBeam's board with Dr. Jaff's expertise in vascular medicine and innovation, aligning with the company's focus on developing advanced cardiac technology, including the 3D-vector electrocardiogram (VECG) platform for home use. The appointment reflects HeartBeam's commitment to leveraging top talent for advancing its cardiac technology solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
management
-
News

HeartBeam Appoints Ken Nelson and Mark Strome to the Board of Directors

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News

HeartBeam Enters into Strategic Alliance Agreement with Samsung

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.26%
Tags
none

FAQ

What is the current stock price of Heartbeam (BEAT)?

The current stock price of Heartbeam (BEAT) is $2.02 as of February 28, 2025.

What is the market cap of Heartbeam (BEAT)?

The market cap of Heartbeam (BEAT) is approximately 65.8M.

What does HeartBeam, Inc. do?

HeartBeam, Inc. develops high-resolution ambulatory ECG solutions for detecting and monitoring cardiac disease outside traditional healthcare settings.

What is unique about HeartBeam's technology?

HeartBeam's technology includes a credit card-sized ECG device and a cloud-based diagnostic system that performs as well as top cardiologists in diagnosing heart attacks.

How does HeartBeam's iCardiologist application work?

The iCardiologist application uses AI and machine learning to continuously improve its diagnostic accuracy and predictive capabilities, assisting cardiologists in patient analysis.

What is VECG technology?

VECG stands for Vector Electrocardiography, a proprietary and patented platform developed by HeartBeam to provide higher-resolution ECG solutions.

Has HeartBeam's technology been validated?

Yes, studies by Harvard Medical School faculty have shown that HeartBeam's performance is equal to or better than world-class cardiologists in diagnosing heart attacks.

Is HeartBeam seeking FDA clearance?

Yes, HeartBeam is currently seeking U.S. Food and Drug Administration (FDA) clearance for its initial telehealth products.

What are the benefits of HeartBeam's ECG solutions?

HeartBeam's solutions offer accessible, high-resolution cardiac monitoring useful outside of traditional healthcare settings, providing early detection and monitoring of cardiac conditions.

Can HeartBeam's technology locate a heart attack?

Yes, the technology can help cardiologists locate a heart attack on a 3D model of the heart using personalized diagnostic thresholds and novel ECG markers.

How is HeartBeam improving cardiac care?

HeartBeam is improving cardiac care by developing practical, high-resolution ECG solutions that provide critical diagnostic tools accessible outside traditional healthcare environments.

Where can I find the latest news on HeartBeam, Inc.?

The latest news and updates on HeartBeam, Inc. can be found on StockTitan and other financial news platforms.
Stock BEAT logo
Heartbeam Inc

Nasdaq:BEAT

BEAT Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

BEAT Stock Data

65.76M
19.29M
29.25%
8.73%
0.47%
Health Information Services
Surgical & Medical Instruments & Apparatus
Link
United States
SANTA CLARA